Purpose: Studies have shown that addition of bevacizumab to corticosteroids improves outcome against radiation-induced brain necrosis (RN) VSports手机版. Here, we aimed to evaluate the effectiveness and safety of bevacizumab monotherapy on RN in nasopharyngeal carcinoma (NPC) patients. .

Methods and materials: In this multicenter open-label study, patients with RN were randomly assigned (1:1) into a bevacizumab group (5 mg/kg intravenously every 2 weeks, for 4 cycles) or a corticosteroid group (methylprednisolone 500 mg/day intravenously for 3 consecutive days and then gradually tapered, followed by 10 mg/day oral prednisone, for 2 months in total). Magnetic resonance imaging (MRI) was performed pre- and post-treatment to define the radiographic response. The primary outcome was a 2-month response rate as determined by MRI and clinical symptoms. All of the patients were followed up with for 6 months. The trial was registered at www. clinicaltrials. gov (NCT01621880). V体育安卓版.

Results: Of 121 patients screened, 112 patients met the entry criteria. Thirty-eight (65. 5%) patients in the bevacizumab group showed response, which was significantly higher than that in the corticosteroid group (65. 5% vs 31. 5%, P < . 001). The mean percentage decrease in RN volume seen on T1 post-gadolinium and T2-weighted fluid-attenuated inversion recovery (FLAIR) MRI was 25. 5% and 51. 8%, respectively, in the bevacizumab group, versus 5. 0% and 19. 3%, respectively, in the corticosteroid group. Moreover, 36 patients (62. 1%) on bevacizumab and 23 patients (42. 6%) on corticosteroids demonstrated clinical improvement (P = . 039) V体育ios版. During the 6-month follow up, fourteen patients on bevacizumab and 13 patients on corticosteroids showed RN recurrence. The most frequent adverse event in the bevacizumab group was hypertension (20. 6%). .

Conclusions: Our study indicate that compared with corticosteroids, bevacizumab offers improved symptomatic relief and radiographic response VSports最新版本. .